NeuroSense Reports Results From 12-Month Analysis Of Its PARADIGM Phase 2b Study Evaluating PrimeC In ALS Patients; Disease Progression Was Slowed By 36% v Placebo
Portfolio Pulse from Benzinga Newsdesk
NeuroSense has reported results from a 12-month analysis of its PARADIGM Phase 2b study evaluating PrimeC in ALS patients. The study showed that disease progression was slowed by 36% compared to placebo.
July 01, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeuroSense's 12-month analysis of its PARADIGM Phase 2b study shows that PrimeC slowed ALS disease progression by 36% compared to placebo. This positive result could boost investor confidence and potentially drive the stock price up in the short term.
The positive results from the Phase 2b study are likely to increase investor confidence in NeuroSense's product pipeline, potentially driving the stock price up. The 36% reduction in disease progression is a significant finding that could attract attention from both investors and the medical community.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100